Drugs / 19-28z T CELLS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01840566 | Apr 2013 → Apr 2027 expected | non-Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 19-28z T CELLS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01840566 ↗ |
| Modality | Cell therapy | “CD19-specific chimeric antigen receptor (CAR) T cells” PMID 31262783 ↗ Jul 2019 |
| Target | CD19 | “CD19-specific chimeric antigen receptor (CAR) T cells” PMID 31262783 ↗ Jul 2019 |